Scancell Holdings Stock

Scancell Holdings ROA 2024

Scancell Holdings ROA

-0.39

Ticker

SCLP.L

ISIN

GB00B63D3314

WKN

A1JZ3D

In 2024, Scancell Holdings's return on assets (ROA) was -0.39, a 232.48% increase from the -0.12 ROA in the previous year.

Scancell Holdings Aktienanalyse

What does Scancell Holdings do?

Scancell Holdings PLC is a biotechnology company specializing in the development of immunotherapies for cancer. The company was founded in 1997 and is headquartered in Nottingham, United Kingdom. Scancell's goal is to improve the lives of patients with cancer by developing innovative therapies that selectively activate the body's immune system. Scancell's business model is based on the research, development, and commercialization of immunotherapies. The company has developed a platform technology called Modified Vaccinia Ankara (MVA), which is a widely used virus in vaccine research and development. Scancell uses this platform technology to develop vaccines that selectively activate the immune system against cancer cells. The company works closely with academic partners and other biotech companies. The company has two main divisions: Scancell Immunotherapy and Scancell Biotherapeutics. Under the Scancell Immunotherapy division, the company develops cancer vaccines. Scancell is actively working on the development of two main products: SCIB1 and Modi-1. SCIB1 is an immunotherapy based on a DNA-based vaccine that activates the immune system to attack cancer cells. This vaccine has been studied in various clinical trials and has shown promising results. SCIB1 has been tested in a Phase II study on patients with advanced melanoma and has triggered a strong immune response in most patients. The company is now working on further developing SCIB1 in clinical trials. Modi-1 is an immunotherapy based on a novel technology called Modified T-cells. These are engineered T-cells that compel the immune system to recognize and attack cancer cells. Modi-1 is still in the development phase and has not yet been tested in clinical trials. Under the Scancell Biotherapeutics division, the company develops antibodies for cancer treatment. The company focuses on developing antibodies that target specific cancer antigens. Scancell has already developed several promising antibody candidates, including AvidiMabTM, an antibody candidate against the CD98 receptor, which is overexpressed in many cancer cells. Scancell is currently listed on the London Stock Exchange and has a market capitalization of around £250 million. The company also has a strong pipeline of products in development and is actively working to realize their potential. Scancell has a strong partnership with AstraZeneca, one of the world's largest pharmaceutical companies, to support its research and development activities. In summary, Scancell is an emerging biotech company specializing in the development of immunotherapies for cancer. The company has a strong pipeline of products in development and works closely with leading scientists and academic institutions. Scancell is a promising company that offers exciting opportunities for both investors and patients. Scancell Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Scancell Holdings's Return on Assets (ROA)

Scancell Holdings's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Scancell Holdings's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Scancell Holdings's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Scancell Holdings’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Scancell Holdings stock

What is the Return on Assets (ROA) of Scancell Holdings this year?

The Return on Assets (ROA) of Scancell Holdings is -0.39 undefined this year.

What was the ROA of Scancell Holdings compared to the previous year?

The ROA of Scancell Holdings has increased by 232.48% compared to the previous year.

What consequences do high ROA have for investors of Scancell Holdings?

A high ROA is advantageous for investors of Scancell Holdings, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Scancell Holdings?

A low ROA can be unfavorable for investors of Scancell Holdings as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Scancell Holdings affect the company?

An increase in ROA of Scancell Holdings can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Scancell Holdings impact the company?

A reduction in the ROA of Scancell Holdings can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Scancell Holdings?

Some factors that can influence the ROA of Scancell Holdings include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Scancell Holdings important for investors?

The ROA of Scancell Holdings is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Scancell Holdings take to improve ROA?

To improve ROA, Scancell Holdings can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Scancell Holdings pay?

Over the past 12 months, Scancell Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Scancell Holdings is expected to pay a dividend of 0 GBP.

What is the dividend yield of Scancell Holdings?

The current dividend yield of Scancell Holdings is .

When does Scancell Holdings pay dividends?

Scancell Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Scancell Holdings?

Scancell Holdings paid dividends every year for the past 0 years.

What is the dividend of Scancell Holdings?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Scancell Holdings located?

Scancell Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Scancell Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Scancell Holdings from 12/11/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 12/11/2024.

When did Scancell Holdings pay the last dividend?

The last dividend was paid out on 12/11/2024.

What was the dividend of Scancell Holdings in the year 2023?

In the year 2023, Scancell Holdings distributed 0 GBP as dividends.

In which currency does Scancell Holdings pay out the dividend?

The dividends of Scancell Holdings are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Scancell Holdings

Our stock analysis for Scancell Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Scancell Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.